September 10, 2025EndocrinologyOpen Access

Emerging mechanisms of therapy resistance in metastatic ER+ breast cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review discusses therapy resistance and disease progression in ER+ breast cancer, highlighting CDK4/6 and PI3K/AKT/mTOR pathways.

Therapy resistance significantly contributes to the recurrence and progression of metastatic ER+ breast cancer.
Nearly 80% of new breast cancer cases are estrogen receptor-positive, indicating a substantial impact on therapy outcomes.
Molecular mechanisms underlying therapy resistance include CDK4/6 inhibitors and PI3K/AKT/mTOR pathway alterations.
Targeting breast cancer stem-like populations may offer new strategies to combat therapy resistance and improve patient outcomes.

Truong et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark